Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of renal cell carcinoma after nephrectomy.
Status In progress
Decision Selected
Process STA 2018
ID number 3810

Provisional Schedule

Expected publication 20 July 2022

Project Team

Project lead Shonagh D'Sylva

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors MSD (pembrolizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Kidney Cancer Support Network
  Kidney Cancer UK
Professional groups Association of Cancer Physicians
  British Uro-oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
12 May 2022 Committee meeting: 1
02 September 2021 Invitation to participate
31 August 2021 We recently contacted all stakeholders for the appraisal of pembrolizumab for adjuvant treatment of renal cell carcinoma regarding a delay to this topic for operational reasons. Pembrolizumab for adjuvant treatment of renal cell carcinoma has now been rescheduled into the work programme. The appraisal is due to start early September 2021 and will be discussed at committee in mid-May 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.
17 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
16 November 2020 - 14 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
02 August 2019 In progress. DHSC referral received 02/08/2019

For further information on our processes and methods, please see our CHTE processes and methods manual